|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$6,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$3,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$5,933
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$9,977
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$189,636
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-03
|
$366,000
|
$366,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Role of NFxB/HIF2a axis in renal cell carcinoma progression
|
5K08CA178168-05
|
$175,163
|
$87,582
|
ABEL, E
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-03
|
$401,456
|
$401,456
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-09
|
$461,999
|
$461,999
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-03S1
|
$29,864
|
$17,022
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-03
|
$2,224,884
|
$1,268,184
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-07
|
$1,414,315
|
$268,720
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
1R03CA212798-01
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
1R03CA219336-01
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Platelets promote growth of ovarian cancer
|
5R01CA177909-05
|
$332,000
|
$166,000
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS
|
5R01CA172623-05
|
$384,803
|
$384,803
|
AFT, REBECCA
|
WASHINGTON UNIVERSITY
|
|
|
High Throughput Mechanical Modulatory Assay for Breast Cancer Drug Testing
|
5R21CA210126-02
|
$207,928
|
$207,928
|
AGAH, MASOUD
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
1R01CA218024-01
|
$445,511
|
$222,756
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-14
|
$428,739
|
$428,739
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
$156,511
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Post-translational control of cancer cell stress response and metastasis
|
5R01CA202027-02
|
$459,505
|
$459,505
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer
|
1R43CA221580-01
|
$225,000
|
$225,000
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-04
|
$584,480
|
$584,480
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Multicellular Cancer Cell Cluster Extravasation through Angiopellosis
|
1F31CA217153-01A1
|
$34,660
|
$34,660
|
ALLEN, TYLER
|
NORTH CAROLINA STATE UNIVERSITY RALEIGH
|
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-03
|
$378,171
|
$189,086
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN
|
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-04
|
$435,560
|
$108,890
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
|
Tumor Plasticity
|
1R35CA220446-01
|
$900,000
|
$900,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
$39,899
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Control of Apoptosis in Cancer by Survivin
|
3R01CA078810-19S1
|
$228,000
|
$228,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Novel Molecular Therapies of Prostate Cancer
|
5P01CA140043-08
|
$1,239,835
|
$1,239,835
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
$740,763
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Control of Apoptosis in Cancer by Survivin
|
5R01CA078810-20
|
$380,000
|
$380,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
|
5R01CA178610-04
|
$316,934
|
$158,467
|
ALUMKAL, JOSHI
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
5R01CA208042-02
|
$363,713
|
$120,025
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
5R01CA169134-05
|
$312,942
|
$156,471
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer
|
1R43CA195882-01A1
|
$300,000
|
$300,000
|
Ammons, William
|
SYNERGYS BIOTHERAPEUTICS, INC.
|
|
|
Role of Splicing Factors in Breast Cancer
|
5R00CA178206-04
|
$249,000
|
$249,000
|
ANCZUKOW-CAMARDA, OLGA
|
JACKSON LABORATORY
|
|
|
Image guided immunotherapy and targeted radionuclide therapy of metastatic melanoma
|
1R01CA214018-01
|
$456,361
|
$456,361
|
ANDERSON, CAROLYN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-04
|
$303,172
|
$303,172
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
|
Nuclear Factor-kappaB in Ovarian Cancer
|
ZIA BC 011054
|
$515,250
|
$103,050
|
Annunziata, Christina
|
CCR (NCI)
|
|
|
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
|
1R01CA196988-01A1
|
$353,419
|
$353,419
|
ANTALIS, TONI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
Non-canonical functions of EZH2 in triple-negative breast cancer
|
5F30CA196084-03
|
$34,645
|
$34,645
|
ANWAR, TALHA
|
UNIVERSITY OF MICHIGAN
|
|
|
Mutant BRAF-regulated transcription factors in melanoma progression
|
5R01CA196278-03
|
$356,850
|
$356,850
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$536,543
|
$182,425
|
Apolo, Andrea
|
CCR (NCI)
|
|
|
Cerenkov imaging for in vivo pH determination of the tumor microenvironment
|
5F31CA206453-02
|
$30,962
|
$15,481
|
ARROYO PACHECO, ALEJANDRO
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
$28,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
$396,800
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
$811,848
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
$15,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-18SB
|
$59,999
|
$7,200
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Total relevant funding to Metastasis for this search: $427,988,852
|
